Across TCGA pan-cancer cohorts, CD300LF mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CD300LF data layer compared with 26 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CD300LF mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CD300LF expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

PDAC, LUAD, and GBM are the cancer types where CD300LF mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	II,III,IV	0.948	0.658	.009	25	view →
LUAD	OS	Median	All	0.928	0.999	.019	16	view →
GBM	DFS	Tertile	All	0.258	0.648	.026	5	view →
UCEC	DFS	Median	All	0.699	1.000	.013	2	view →
LSCC	DFS	Quartile	II,III,IV	0.553	0.929	.032	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: CD300LF tumor-vs-normal RNA expression · all CD300LF data types